Effect of new modalities of treatment on physicians’ management plan for patients with spinal muscular atrophy

References

1. ↵
   1. Prior TW

   (2008) Carrier screening for spinal muscular atrophy. Genet Med 10, 840–842.
2. 1. Sugarman EA,
   2. Nagan N,
   3. Zhu H,
   4. Akmaev VR,
   5. Zhou Z,
   6. Rohlfs EM,
   7. et al.

   (2012) Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy:clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet 20, 27–32.
3. 1. Pearn J

   (1978) Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 15, 409–413.
4. 1. Lefebvre S,
   2. Bürglen L,
   3. Reboullet S,
   4. Clermont O,
   5. Burlet P,
   6. Viollet L,
   7. et al.

   (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165.
5. ↵
   1. Prior TW

   (2010) Spinal muscular atrophy:a time for screening. Curr Opin Pediatr 22, 696–702.
6. ↵
   1. Ogino S,
   2. Leonard DG,
   3. Rennert H,
   4. Ewens WJ,
   5. Wilson RB

   (2002) Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet 110, 301–307.
7. ↵
   1. Wang CH,
   2. Bonnemann CG,
   3. Rutkowski A,
   4. Sejersen T,
   5. Bellini J,
   6. Battista V,
   7. et al.

   (2010) Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol 25, 1559–1581.
8. ↵
   1. Arnold WD,
   2. Kassar D,
   3. Kissel JT

   (2015) Spinal muscular atrophy:diagnosis and management in a new therapeutic era. Muscle Nerve 51, 157–167.
9. ↵
   1. Wang CH,
   2. Finkel RS,
   3. Bertini ES,
   4. Schroth M,
   5. Simonds A,
   6. Wong B,
   7. et al.

   (2007) Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22, 1027–1049.
10. ↵
    1. Kayadjanian N,
    2. Burghes A,
    3. Finkel RS,
    4. Mercuri E,
    5. Rouault F,
    6. Schwersenz I,
    7. et al.

    (2013) SMA-EUROPE workshop report:Opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe. Orphanet J Rare Dis 8, 44.
11. ↵
    1. Mercuri E,
    2. Darras BT,
    3. Chiriboga CA,
    4. Day JW,
    5. Campbell C,
    6. Connolly AM,
    7. et al.

    (2018) Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med 378, 625–635.
12. ↵
    1. Jan MM

    (2016) Neuroscience Forum:a scientific group on smartphones. Ann Saudi Med 36, 235.
13. ↵
    1. Oskoui M,
    2. Levy G,
    3. Garland CJ,
    4. Gray JM,
    5. O'Hagen J,
    6. De Vivo DC,
    7. et al.

    (2007) The changing natural history of spinal muscular atrophy type 1. Neurology 69, 1931–1936.
14. ↵
    1. Mercuri E,
    2. Finkel RS,
    3. Muntoni F,
    4. Wirth B,
    5. Montes J,
    6. Main M,
    7. et al.

    (2018) Diagnosis and management of spinal muscular atrophy:Part 1:Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 28, 103–115.
15. ↵
    1. Finkel RS,
    2. Mercuri E,
    3. Meyer OH,
    4. Simonds AK,
    5. Schroth MK,
    6. Graham RJ,
    7. et al.

    (2018) Diagnosis and management of spinal muscular atrophy:Part 2:Pulmonary and acute care;medications, supplements and immunizations;other organ systems;and ethics. Neuromuscul Disord 28, 197–207.
16. ↵
    1. Benson RC,
    2. Hardy KA,
    3. Gildengorin G,
    4. Hsia D

    (2012) International survey of physician recommendation for tracheostomy for Spinal Muscular Atrophy Type I. Pediatr Pulmonol 47, 606–611.
17. ↵
    1. Finkel RS,
    2. Mercuri E,
    3. Darras BT,
    4. Connolly AM,
    5. Kuntz NL,
    6. Kirschner J,
    7. et al.

    (2017) Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 377, 1723–1732.
18. ↵
    1. Oskoui M,
    2. Ng P,
    3. Liben S,
    4. Zielinski D

    (2017) Physician driven variation in the care of children with spinal muscular atrophy type 1. Pediatr Pulmonol 52, 662–668.
19. ↵
    1. Temsah MA,
    2. Al-Sohime FM,
    3. Bashiri FA,
    4. Al-Eyadhy AA,
    5. Hasan GM,
    6. Alhaboob AA

    (2018) Respiratory support attitudes among pediatric intensive care staff for spinal muscular atrophy patients in Saudi Arabia. Neurosciences (Riyadh) 23, 62–65.
20. ↵
    1. Mendell JR,
    2. Al-Zaidy S,
    3. Shell R,
    4. Arnold WD,
    5. Rodino-Klapac LR,
    6. Prior TW,
    7. et al.

    (2017) Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med 377, 1713–1722.